Tocilizumab, sarilumab and anakinra in critically ill patients with COVID-19: a randomised, controlled, open-label, adaptive platform trial
Lennie Derde(University Medical Center Utrecht), Ville Pettilä(University of Helsinki), Andrew T. King(NHS Blood and Transplant), Rashan Haniffa(University of Oxford), James Galea(Cardiff University), Nao Ichihara(The University of Tokyo), Lise J Estcourt(NHS Blood and Transplant), Yaseen M. Arabi(World Health Organization), Susan C. Morpeth, Allen Cheng(Australian Regenerative Medicine Institute), Patrick R. Lawler(McGill University Health Centre), Kayode Ogungbenro(University of Manchester), Alistair Nichol(University College Dublin), Nicola Cooper(Birmingham Women's Hospital), Asad E. Patanwala(The University of Sydney), Meredith Buxton(Center for Effective Global Action), M. G. Netea(Radboud University Nijmegen), Florian Mayr(Queen's University Belfast), Anthony Gordon(University of Copenhagen), Marc J. M. Bonten(Utrecht University), Rachael Parke(University of Auckland), Paul Mouncey(Intensive Care National Audit & Research Centre), Richard Beasley(Medical Research Institute of New Zealand), Srinivas Murthy, Shay McGuinness, David T. Huang(University of Pittsburgh), Frank M. Brunkhorst, Djillali Annane(Hôpital Raymond-Poincaré), Edward Litton(The University of Western Australia), Michelle A. Detry(Berry & Associates (United States)), Bryan J. McVerry(University of Pittsburgh), Thomas Hills(Auckland City Hospital), Matthew E. Cove(National University Hospital), Anna McGlothlin(Berry & Associates (United States)), Kathy Rowan(Intensive Care National Audit & Research Centre), Charlotte Bradbury(University of Bristol), Olaf L. Cremer(University Medical Center Utrecht), Farah Al-Beidh(Imperial College Healthcare NHS Trust), Helen L. Leavis(University Medical Center Utrecht), Daniel F McAuley(Royal Prince Alfred Hospital), Abigail Beane(University of Oxford), Mark Fitzgerald(Berry & Associates (United States)), Adrian Buzgau(Monash University), Herman Goossens(Antwerp University Hospital), John C. Marshall(St. Michael's Hospital), Eamon Duffy(Auckland City Hospital), Roger J. Lewis(Berry & Associates (United States)), Katrina Orr(University of Auckland)
Cited by 12
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
|Intensive Care Medicine|2021|5.1k